Advertisement
MRK vs PFE
Which Stock Would AI Choose? Merck & Co. (MRK) vs. Pfizer Inc. (PFE) Stock Comparison
Key Takeaways
- MRK reported Q1 2026 revenue of $16.3 billion, surpassing estimates and prompting a raised full-year sales guidance to $66.4 billion, driven by oncology strength.
- PFE shares trade at a lower price-to-earnings (P/E) ratio of 19.4 compared to MRK's 31.5, offering relative value amid diversification efforts.
- MRK boasts a larger market capitalization of $277 billion versus PFE's $150 billion, reflecting stronger investor confidence in its growth trajectory.
- Both stocks have shown resilience in recent market activity, but MRK delivered superior one-year returns of approximately 35% compared to PFE's 23%.
- Recent sentiment favors MRK due to Keytruda sales and new approvals, while PFE navigates post-COVID challenges with pipeline catalysts.
Introduction
Merck & Co. (MRK) and Pfizer Inc. (PFE) stand as pharmaceutical powerhouses, dominating oncology, vaccines, and innovative therapies. This comparison analyzes their recent market positioning, performance metrics, and growth drivers amid evolving healthcare demands. Traders seeking momentum plays and investors eyeing dividend stability or value opportunities will find value in understanding their relative strengths, especially as sector rotation influences big pharma stocks.
MRK Overview and Recent Performance
Merck & Co. (MRK) focuses on oncology, vaccines, and hospital products, with blockbuster Keytruda anchoring revenue. In recent weeks, shares hovered around $112, reflecting a year-to-date gain amid broader market volatility. Q1 2026 results highlighted oncology sales up 8%, total revenue of $16.3 billion (exceeding forecasts), and elevated full-year guidance, boosting sentiment. New approvals for HIV regimens and expansions in rare diseases have countered patent concerns, supporting upward momentum despite a monthly dip. Keytruda's dominance and pipeline progress have sustained positive relative performance versus peers.
PFE Overview and Recent Performance
Pfizer Inc. (PFE) maintains a broad portfolio spanning oncology, immunology, and rare diseases, leveraging acquisitions for diversification post-COVID. Trading near $26 recently, the stock has posted modest year-to-date advances of around 5%. Recent quarters showed revenue stability at $17.6 billion in Q4 FY25, with earnings per share (EPS) beats, though growth has moderated. Pipeline advancements, including breast cancer approvals and dividend reliability, have tempered downside risks. Sentiment reflects value appeal amid sector pressures, with shares outperforming in select pullbacks.
Trending AI Robots
Tickeron's Trending AI Robots page curates the top performers from over 350 AI trading bots that analyze thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies, timeframes (from 15 minutes to days), and styles, delivering real-time signals for copy trading. Standouts show annualized returns up to 163%, win rates ranging 51-88%, and profit factors highlighting efficiency in sectors like semiconductors and industrials. Only the most suitable for prevailing conditions earn a spot, based on metrics like profit-to-drawdown ratios. Explore these tools to align bots with your trading approach.
Head-to-Head Comparison
Both MRK and PFE operate in big pharma, but MRK emphasizes oncology growth via Keytruda, while PFE balances vaccines and acquisitions for broader exposure. MRK's revenue trajectory outpaces with recent beats and higher guidance, contrasting PFE's steadier but lower growth. Momentum favors MRK (1-year up 35% vs. 23%), yet PFE offers cheaper valuation (P/E 19 vs. 32) and higher yield potential. Risks include patent expirations for both, with MRK facing Keytruda cliffs and PFE COVID revenue normalization. Market sentiment tilts toward MRK's catalysts.
Tickeron AI Verdict
Tickeron's AI currently leans toward MRK based on superior trend consistency, recent earnings momentum, oncology catalysts, and relative stability versus PFE. While PFE provides value, MRK's positioning suggests higher probability of outperformance in the near term amid favorable sector dynamics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRK is a Buy and PFE is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRK’s FA Score shows that 3 FA rating(s) are green whilePFE’s FA Score has 0 green FA rating(s).
- MRK’s FA Score: 3 green, 2 red.
- PFE’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRK’s TA Score shows that 6 TA indicator(s) are bullish while PFE’s TA Score has 4 bullish TA indicator(s).
- MRK’s TA Score: 6 bullish, 4 bearish.
- PFE’s TA Score: 4 bullish, 5 bearish.
Price Growth
MRK (@Pharmaceuticals: Major) experienced а +3.28% price change this week, while PFE (@Pharmaceuticals: Major) price change was +2.75% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +4.12%. For the same industry, the average monthly price growth was +16.27%, and the average quarterly price growth was +11.13%.
Reported Earning Dates
MRK is expected to report earnings on Aug 04, 2026.
PFE is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+4.12% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| MRK | PFE | MRK / PFE | |
| Capitalization | 320B | 139B | 230% |
| EBITDA | 19.4B | 17.2B | 113% |
| Gain YTD | 24.889 | 0.946 | 2,631% |
| P/E Ratio | 32.53 | 19.15 | 170% |
| Revenue | 65.8B | 63.3B | 104% |
| Total Cash | N/A | 13.1B | - |
| Total Debt | 49.1B | 63.7B | 77% |
MRK | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 14 Undervalued | 51 Fair valued | |
PROFIT vs RISK RATING 1..100 | 41 | 100 | |
SMR RATING 1..100 | 47 | 77 | |
PRICE GROWTH RATING 1..100 | 12 | 60 | |
P/E GROWTH RATING 1..100 | 6 | 41 | |
SEASONALITY SCORE 1..100 | 47 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRK's Valuation (14) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (51). This means that MRK’s stock grew somewhat faster than PFE’s over the last 12 months.
MRK's Profit vs Risk Rating (41) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (100). This means that MRK’s stock grew somewhat faster than PFE’s over the last 12 months.
MRK's SMR Rating (47) in the Pharmaceuticals Major industry is in the same range as PFE (77). This means that MRK’s stock grew similarly to PFE’s over the last 12 months.
MRK's Price Growth Rating (12) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (60). This means that MRK’s stock grew somewhat faster than PFE’s over the last 12 months.
MRK's P/E Growth Rating (6) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (41). This means that MRK’s stock grew somewhat faster than PFE’s over the last 12 months.
| MRK | PFE | |
|---|---|---|
| RSI ODDS (%) | 5 days ago 51% | 5 days ago 57% |
| Stochastic ODDS (%) | 5 days ago 63% | 5 days ago 44% |
| Momentum ODDS (%) | 5 days ago 56% | 5 days ago 58% |
| MACD ODDS (%) | 5 days ago 52% | 5 days ago 64% |
| TrendWeek ODDS (%) | 5 days ago 55% | 5 days ago 55% |
| TrendMonth ODDS (%) | 5 days ago 54% | 5 days ago 55% |
| Advances ODDS (%) | 8 days ago 54% | 8 days ago 55% |
| Declines ODDS (%) | 6 days ago 51% | 6 days ago 58% |
| BollingerBands ODDS (%) | 5 days ago 57% | 5 days ago 56% |
| Aroon ODDS (%) | 5 days ago 64% | 5 days ago 59% |
Advertisement